RAPT - RAPT Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
Total Revenue
0
0
0
Cost of Revenue
-
-
-
Gross Profit
-
-
-
Operating Expenses
Research Development
33,698
31,767
25,618
Selling General and Administrative
7,021
5,180
3,713
Total Operating Expenses
40,719
36,947
29,331
Operating Income or Loss
-40,719
-36,947
-29,331
Interest Expense
-
-
-
Total Other Income/Expenses Net
1,193
800
216
Income Before Tax
-39,526
-36,147
-29,115
Income Tax Expense
-
-
-
Income from Continuing Operations
-39,526
-36,147
-29,115
Net Income
-39,526
-36,147
-29,115
Net Income available to common shareholders
-39,526
-36,147
-29,115
Reported EPS
Basic
-
-2.50
-2.01
Diluted
-
-2.50
-2.01
Weighted average shares outstanding
Basic
-
14,461
14,461
Diluted
-
14,461
14,461
EBITDA
-
-35,710
-27,947